- In January 2025, Lantheus Holdings announced its acquisition of Life Molecular Imaging for USD 350 million, aimed at advancing its position in the Alzheimer's disease radiodiagnostic market. The deal will enhance Lantheus' capabilities with Neuraceq, an FDA-approved PET imaging agent for detecting beta-amyloid plaques in patients with cognitive impairment. This acquisition will expand their research and development capacity, commercial infrastructure, and global presence, facilitating growth in Alzheimer's diagnostics. The transaction is expected to boost Lantheus' revenue and impact patient care globally, especially for those with Alzheimer's and related cognitive conditions
- In August 2024, Siemens Healthineers received FDA clearance for the Biograph Trinion PET/CT scanner. This advanced scanner enhances diagnostic capabilities by providing high spatial resolution and ultrafast time-of-flight performance. It enables rapid examinations with minimal radiation exposure, improving patient safety and comfort. The scanner’s energy-efficient design and scalable features help reduce energy consumption, making it both sustainable and cost-effective for healthcare providers. The integration of AI technology further streamlines workflows, allowing for more consistent and accurate results, benefiting both clinicians and patients by enhancing diagnostic efficiency and accessibility
- In June 2024, Positron Corporation announced the sale of its Attrius PET system to a prominent cardiovascular practice in Michigan. The Attrius is a 2D quantitative PET scanner designed for nuclear cardiology, offering high-resolution imaging and robust blood flow data for accurate coronary flow reserve measurements. This system is expected to enhance advanced cardiac diagnostics. Positron will install the system by Q4 2024, offering a Lease to Own Program, which allows practices to acquire the PET scanner without upfront capital expenditure. This model aims to make cardiac PET imaging more accessible to nuclear imaging practices
- In October 2022, Spectrum Dynamics announced a significant development in digital nuclear medicine imaging with the introduction of the capability to image high-energy isotopes using solid-state detector technology. This feature is part of the new VERITON-CT 400 Series Digital SPECT/CT scanners, which offer enhanced imaging for a wide range of applications, including total body, brain, and heart imaging. The 360°-CZT-based configuration provides improved precision and broader imaging coverage, enhancing diagnostic capabilities. This innovation promises to streamline nuclear medicine workflows and improve diagnostic accuracy in various clinical settings
